Results 71 to 80 of about 15,364 (179)

Eltrombopag for the treatment of aplastic anemia: current perspectives

Drug Design, Development and Therapy, 2016
Su Han Lum, John D GraingerDepartment of Blood and Marrow Transplant, Royal Manchester Children’s Hospital, Manchester, UK Abstract: Aplastic anemia (AA) is a potential life-threatening hematopoietic stem cell (HSC) disorder resulting in cytopenia.
Lum SH, Grainger JD
doaj  

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy

Drug Design, Development and Therapy, 2017
David Buchbinder, Diane Nugent, Loan Hsieh Division of Hematology, CHOC Children’s Hospital and UC Irvine Medical Center, CA, USA Abstract: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia.
Buchbinder D, Nugent D, Hsieh L
doaj  

Thrombopoietin

Drugs of the Future, 1996
S. Lok, D.C. Foster
  +6 more sources

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease

Journal of Blood Medicine, 2019
Abraham Z Cheloff, Hanny Al-Samkari Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USACorrespondence: Hanny Al-SamkariDivision of Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson ...
Cheloff AZ, Al-Samkari H
doaj  

Thrombopoietin. [PDF]

BMJ, 1970
openaire   +2 more sources

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

Biologics: Targets & Therapy, 2009
Ara Metjian1, Charles S Abrams21Department of Medicine, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USAAbstract: Decades of basic science and clinical research have led to an ...
Ara Metjian, Charles S Abrams
doaj  

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis. [PDF]

Front Public Health
Jin S, Hu Z, Jin Y, Lv W, Song Z, Zeng S, Wu M.   +6 more
europepmc   +1 more source

No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. [PDF]

Exp Ther Med
Shen N, Wu R, Lu T, Liu S, Jiang Y, Yan J, Ning T, Dong C, Li J, Zhu S.   +9 more
europepmc   +1 more source

Pembrolizumab-Induced Aplastic Anemia Successfully Treated With Thrombopoietin Receptor Agonist in a Patient With Lung Adenocarcinoma: A Case Report and Literature Review. [PDF]

Cureus
Namba K, Isobe K, Nakao S, Hiruta N, Wakabayashi H.   +4 more
europepmc   +1 more source

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Ohta R, Ryu Y, Ichinose K.
europepmc   +1 more source